-
公开(公告)号:JPWO2003035074A1
公开(公告)日:2005-02-10
申请号:JP2003537641
申请日:2002-03-18
申请人: 小野薬品工業株式会社
IPC分类号: A61K31/499 , A61K31/5377 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/06 , A61P3/10 , A61P5/38 , A61P9/04 , A61P9/06 , A61P11/00 , A61P11/06 , A61P11/10 , A61P11/14 , A61P13/12 , A61P15/10 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/06 , A61P23/00 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/04 , A61P31/08 , A61P31/10 , A61P31/18 , A61P35/00 , A61P35/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/10
CPC分类号: C07D471/10 , A61K31/499 , A61K45/06 , A61K2300/00
摘要: 一般式(I)(式中、すべての記号は後記と同じ意味を表わす。)で示されるトリアザスピロ[5.5]ウンデカン誘導体、それらの四級アンモニウム塩、それらのN−オキシドまたはそれらの非毒性塩と、少なくとも1種類のチトクロムP450アイソザイム3A4阻害剤および/または少なくとも1種類のP糖タンパク質阻害剤との組み合わせからなる医薬。上記組み合わせからなる医薬により、一般式(I)で示される化合物の生物学的利用能が高まり、種々の疾患治療において経口剤として有効に利用できる。
-
2.
公开(公告)号:JP4826282B2
公开(公告)日:2011-11-30
申请号:JP2006046815
申请日:2006-02-23
申请人: 小野薬品工業株式会社
IPC分类号: A61K31/16 , C07C243/24 , A61K31/165 , A61K31/197 , A61K31/341 , A61K31/351 , A61K31/40 , A61K31/4015 , A61K31/4025 , A61K31/4035 , A61K31/4152 , A61K31/4166 , A61K31/4168 , A61K31/4188 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , A61K31/4402 , A61K31/454 , A61K31/5375 , A61P1/16 , A61P3/00 , A61P3/14 , A61P7/00 , A61P9/00 , A61P11/00 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C243/34 , C07C251/76 , C07C251/84 , C07C251/86 , C07D207/22 , C07D207/263 , C07D207/404 , C07D207/50 , C07D209/46 , C07D209/48 , C07D211/28 , C07D211/72 , C07D211/86 , C07D211/98 , C07D213/53 , C07D213/70 , C07D213/76 , C07D213/77 , C07D213/78 , C07D231/08 , C07D233/38 , C07D233/52 , C07D233/80 , C07D239/10 , C07D239/18 , C07D239/36 , C07D241/08 , C07D241/18 , C07D263/26 , C07D263/28 , C07D265/08 , C07D265/10 , C07D265/32 , C07D265/33 , C07D275/02 , C07D275/03 , C07D275/06 , C07D277/18 , C07D277/36 , C07D277/50 , C07D277/54 , C07D277/60 , C07D277/82 , C07D279/02 , C07D279/06 , C07D279/12 , C07D285/10 , C07D285/16 , C07D307/52 , C07D309/04 , C07D309/20 , C07D309/28 , C07D335/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/04 , C07D513/10 , C07F9/59 , C07F9/6558
CPC分类号: C07D209/48 , A61K31/16 , A61K31/165 , A61K31/341 , A61K31/351 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/4152 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , C07C243/34 , C07C251/76 , C07C251/84 , C07C251/86 , C07C2601/08 , C07C2601/14 , C07D207/22 , C07D207/50 , C07D209/46 , C07D211/28 , C07D211/72 , C07D211/86 , C07D211/98 , C07D213/70 , C07D213/76 , C07D213/77 , C07D213/78 , C07D233/38 , C07D233/52 , C07D233/80 , C07D239/10 , C07D239/18 , C07D239/36 , C07D241/08 , C07D241/18 , C07D263/26 , C07D263/28 , C07D265/08 , C07D265/10 , C07D265/33 , C07D275/02 , C07D275/03 , C07D275/06 , C07D277/18 , C07D277/36 , C07D277/50 , C07D277/54 , C07D277/60 , C07D277/82 , C07D279/02 , C07D279/06 , C07D279/12 , C07D285/10 , C07D285/16 , C07D309/04 , C07D309/28 , C07D335/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D513/10 , C07F9/591 , C07F9/65583
摘要: The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).
-
-
4.
公开(公告)号:JP3812678B2
公开(公告)日:2006-08-23
申请号:JP2004501947
申请日:2003-04-24
申请人: 小野薬品工業株式会社
IPC分类号: C07C243/24 , C07D413/12 , A61K31/16 , A61K31/165 , A61K31/341 , A61K31/351 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/4152 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , C07C243/34 , C07C251/76 , C07C251/84 , C07C251/86 , C07D207/22 , C07D207/50 , C07D209/46 , C07D209/48 , C07D211/28 , C07D211/72 , C07D211/86 , C07D211/98 , C07D213/70 , C07D213/76 , C07D213/77 , C07D213/78 , C07D233/38 , C07D233/52 , C07D233/80 , C07D239/10 , C07D239/18 , C07D239/36 , C07D241/08 , C07D241/18 , C07D263/26 , C07D263/28 , C07D265/08 , C07D265/10 , C07D265/32 , C07D265/33 , C07D275/02 , C07D275/03 , C07D275/06 , C07D277/18 , C07D277/36 , C07D277/50 , C07D277/54 , C07D277/60 , C07D277/82 , C07D279/02 , C07D279/06 , C07D279/12 , C07D285/10 , C07D285/16 , C07D309/04 , C07D309/28 , C07D335/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D513/10 , C07F9/59 , C07F9/6558
CPC分类号: C07D209/48 , A61K31/16 , A61K31/165 , A61K31/341 , A61K31/351 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/4152 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , C07C243/34 , C07C251/76 , C07C251/84 , C07C251/86 , C07C2601/08 , C07C2601/14 , C07D207/22 , C07D207/50 , C07D209/46 , C07D211/28 , C07D211/72 , C07D211/86 , C07D211/98 , C07D213/70 , C07D213/76 , C07D213/77 , C07D213/78 , C07D233/38 , C07D233/52 , C07D233/80 , C07D239/10 , C07D239/18 , C07D239/36 , C07D241/08 , C07D241/18 , C07D263/26 , C07D263/28 , C07D265/08 , C07D265/10 , C07D265/33 , C07D275/02 , C07D275/03 , C07D275/06 , C07D277/18 , C07D277/36 , C07D277/50 , C07D277/54 , C07D277/60 , C07D277/82 , C07D279/02 , C07D279/06 , C07D279/12 , C07D285/10 , C07D285/16 , C07D309/04 , C07D309/28 , C07D335/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D513/10 , C07F9/591 , C07F9/65583
摘要: The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).
-
公开(公告)号:JPWO2003091202A1
公开(公告)日:2005-09-02
申请号:JP2004501947
申请日:2003-04-24
申请人: 小野薬品工業株式会社
IPC分类号: C07C243/24 , C07C243/34 , A61K31/16 , A61K31/165 , A61K31/341 , A61K31/351 , A61K31/40 , A61K31/4015 , A61K31/4025 , A61K31/4035 , A61K31/4152 , A61K31/4166 , A61K31/4168 , A61K31/4188 , A61K31/421 , A61K31/422 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , A61K31/4402 , A61K31/4409 , A61K31/45 , A61K31/454 , A61K31/502 , A61K31/506 , A61K31/5375 , A61K31/54 , A61K31/541 , A61P1/16 , A61P3/00 , A61P7/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P29/00 , A61P37/00 , A61P43/00 , C07C251/72 , C07C251/76 , C07C251/84 , C07C251/86 , C07D207/22 , C07D207/263 , C07D207/408 , C07D207/50 , C07D209/46 , C07D209/48 , C07D211/28 , C07D211/72 , C07D211/86 , C07D211/98 , C07D213/53 , C07D213/70 , C07D213/76 , C07D213/77 , C07D213/78 , C07D231/08 , C07D233/38 , C07D233/52 , C07D233/80 , C07D239/10 , C07D239/18 , C07D239/36 , C07D241/08 , C07D241/18 , C07D263/26 , C07D263/28 , C07D265/08 , C07D265/10 , C07D265/32 , C07D265/33 , C07D275/02 , C07D275/03 , C07D275/06 , C07D277/18 , C07D277/36 , C07D277/50 , C07D277/54 , C07D277/60 , C07D277/82 , C07D279/02 , C07D279/06 , C07D279/12 , C07D285/10 , C07D285/16 , C07D307/52 , C07D309/04 , C07D309/06 , C07D309/28 , C07D335/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D513/04 , C07D513/10 , C07F9/59 , C07F9/6558
CPC分类号: C07D209/48 , A61K31/16 , A61K31/165 , A61K31/341 , A61K31/351 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/4152 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , C07C243/34 , C07C251/76 , C07C251/84 , C07C251/86 , C07C2601/08 , C07C2601/14 , C07D207/22 , C07D207/50 , C07D209/46 , C07D211/28 , C07D211/72 , C07D211/86 , C07D211/98 , C07D213/70 , C07D213/76 , C07D213/77 , C07D213/78 , C07D233/38 , C07D233/52 , C07D233/80 , C07D239/10 , C07D239/18 , C07D239/36 , C07D241/08 , C07D241/18 , C07D263/26 , C07D263/28 , C07D265/08 , C07D265/10 , C07D265/33 , C07D275/02 , C07D275/03 , C07D275/06 , C07D277/18 , C07D277/36 , C07D277/50 , C07D277/54 , C07D277/60 , C07D277/82 , C07D279/02 , C07D279/06 , C07D279/12 , C07D285/10 , C07D285/16 , C07D309/04 , C07D309/28 , C07D335/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D513/10 , C07F9/591 , C07F9/65583
摘要: 一般式(I)で示されるジケトヒドラジン誘導体、およびその薬学的に許容される塩に関する(式中の記号は明細書に記載の通り。)。一般式(I)で示される化合物は、システインプロテアーゼ阻害活性を有し、炎症性疾患、免疫疾患、虚血性疾患、呼吸器系疾患、循環器系疾患、血液疾患、神経疾患、肝・胆道疾患、骨・関節疾患、代謝性疾患等の治療剤として有用である。また、エラスターゼ阻害活性を有するため、COPD(慢性閉塞性肺疾患)などの治療剤としても有用である。
-
-
-
-